Journals / Türk Osteoporoz Dergisi / 2020 / Cilt: 26 - Sayı: 3

Review of Causes of Secondary Osteoporosis and Its Relationship with Fracture

Sekonder Osteoporoz Nedenleri ve Kırık İlişkisinin Literatür ile Gözden Geçirilmesi

Pages
180–185
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These situations should not be ignored while evaluating patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Osteoporosis (OP) is a skeletal disease characterised by low bone mass, which may occur due to primary or secondary reasons, and is known to increase the risk of fracture.
📊
Key Findings & Data:Demographic data (age, sex, etc.), comorbidities, drugs and fracture history of patients with secondary OP were obtained from the file information.Results: A total of 2,199 patients with OP were reviewed and 341 patients with secondary OP were included in the study.
💡
Conclusion & Impact:These situations should not be ignored while evaluating patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Osteoporosis (OP) is a skeletal disease characterised by low bone mass, which may occur due to primary or secondary reasons, and is known to increase the risk of fracture. The present study aimed to investigate the frequency and reasons for the diagnosis of secondary OP in patients presenting to our clinic and its relationship with fracture.Materials and Methods: Medical records of patients who came to our outpatient clinic with OP diagnosis were retrospectively reviewed. Demographic data (age, sex, etc.), comorbidities, drugs and fracture history of patients with secondary OP were obtained from the file information.Results: A total of 2,199 patients with OP were reviewed and 341 patients with secondary OP were included in the study. The most common causes of secondary OP were malignancy (38.4%), drug use (24.6%), rheumatologic diseases (17.3%). In addition, 94 patients had fractures and the mean age of these patients was statistically higher than those without fractures (p=0.008). Furthermore, the fracture rate was significantly higher in patients with chronic renal failure (CRF) (p= 0.034) and parathyroid adenoma (p=0.031) than those without these conditions.Conclusion: Causes of secondary OP and fracture rates were determined in patients with OP. Age was associated with CRF and parathyroid adenoma fracture rates. These situations should not be ignored while evaluating patients.

Özet

Amaç: Osteoporoz (OP), kırık riskinde artış yapan, primer ya da sekonder nedenlerle ortaya çıkabilen, düşük kemik kütlesi ile karakterize bir iskelet hastalığıdır. Bu çalışmanın amacı, kliniğimize başvuran hastaların ne sıklıkta ve hangi nedenlerle sekonder OP tanısı aldığını ve bunun kırıkla ilişkisini incelemektir.Gereç ve Yöntem: Polikliniğimize gelerek OP tanısı alan hastaların dosyaları retrospektif olarak incelendi. Sekonder OP tanısı alan hastaların demografik verileri (yaş, cinsiyet), ek hastalıkları, kullandığı ilaçlar ve kırık öyküleri dosya bilgilerinden elde edildi. Bulgular: OP tanısı alan 2.199 hasta dosyası incelendi ve sekonder OP olan 341 hasta çalışmaya dahil edildi. Sekonder OP için en sık 3 neden malignite (%38,4), ilaç kullanımı (%24,6) ve romatolojik hastalıklar (%17,3) idi. Doksan dört hastada kırık bulunurken, bu hastaların yaş ortalaması kırığı olmayanlara göre istatistiksel olarak daha yüksekti (p=0,008). Ayrıca kronik böbrek yetersizliği (KBY) (p=0,034) ve paratiroid adenomu (p=0,031) olan hastalarda kırık oranı olmayanlara göre istatistiksel olarak anlamlı düzeyde yüksekti.Sonuç: Osteoporoz tanılı hastalarda sıklığa göre sekonder OP nedenleri ve kırık oranları belirlenmiştir. Yaş, KBY ve paratiroid adenomu ile kırık oranları ilişkili bulunduğundan hastalar sorgulanırken gözden kaçırılmamalıdır.

🔖

Cite This Article

ALTAŞ, E. U., ONAT, Ş. Ş., BİLİR, İ., ÖZ, B. (2022). Review of Causes of Secondary Osteoporosis and Its Relationship with Fracture. Türk Osteoporoz Dergisi, Cilt: 26 - Sayı: 3, 180–185. https://ajindex.com/articles/639629

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis: report of a WHO scientific group. Technical Report Series 921. Geneva: World Health Organization
  2. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008
  3. Liao CY, Chung CH, Chu P, Wei KY, Feng TM, Lin FH, et al. Increased risk of osteoporosis in patients with primary biliary cirrhosis. PLoS One 2018
  4. e0194418. 4. Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep 2013
  5. Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline. J Clin Oncol 2019
  6. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006
  7. Handforth C, D’Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int 2018
  8. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects:new evidence defining etiology and strategies for management. Breast Cancer Res 2011
  9. Davidge Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011
  10. Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 2017
  11. Ryan AM, Power DG, Daly L, Cushen SJ, Bhuachalla EN, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016
  12. Cağlayan A, Gümüşel BK, Başaran N. Secondary osteoporosis ınduced by hormonal therapy and treatment approaches:Review. Turkiye Klinikleri J Pharm Sci 2013
  13. Berkit IK, Turan Y, Şendur OF. Steroid Induced Osteoporosis. Turk J Osteoporos 2009
  14. Uygur MM, Yavuz DG. Glukokortikoid Osteoporozu. Turkiye Klinikleri J Endocrin-Special Topics 2017
  15. Benlidayı IC. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2018
  16. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006
  17. Kim SM, Kim KM, Kim BT, Joo NS, Kim KN, Lee DJ. Correlation of undercarboxylated osteocalcin (ucOC) concentration and bone density wi